BCF publishes two new individual publications The Bone and Tumor Base is announcing the publishing of two new patient publications on Discomfort Administration and Physical Therapy and other Rehabilitation Therapies. Various other publication topics include: Breasts Cancer, Prostate Tumor, Lung Tumor, Osteonecrosis of the Jaw, Vitamin D, Surgery, Osteosarcoma and Myeloma. All publications can be found free of charge, both in online and printing studied chemical formula . BCF, founded in 2007, can be an information source for patients and medical researchers whose mission would be to provide details for cancer patients, healthcare professionals and the general public on the procedure and factors behind cancer involving bone.
Several studies show that galectin-3 might provide precious insight about heart failing and its underlying disease processes. The BGM Galectin-3 check happens to be available for clinical only use in europe and certain other Europe as an assist in the stratification of patients identified as having heart failing. The BGM Galectin-3 test isn’t designed for distribution or sale in the United States or Canada. THE BUSINESS has submitted a 510 application to get clearance from the U.S. Food and Drug Administration to market the test in the usa.. BG Medicine launches fresh, CE-marked galectin-3 test BG Medication, Inc., a privately-held programmer of biomarker-based in vitro diagnostics, today announced the commercial start in the European Union of a fresh, CE-marked check for the measurement of galectin-3 in human being plasma or serum.